These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25450861)

  • 21. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
    Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
    Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
    Schiff R; Massarweh S; Shou J; Osborne CK
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
    Gionet N; Jansson D; Mader S; Pratt MA
    J Cell Biochem; 2009 Jun; 107(3):448-59. PubMed ID: 19350539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
    Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity.
    Likhite VS; Stossi F; Kim K; Katzenellenbogen BS; Katzenellenbogen JA
    Mol Endocrinol; 2006 Dec; 20(12):3120-32. PubMed ID: 16945990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta.
    Quaedackers ME; Van Den Brink CE; Wissink S; Schreurs RH; Gustafsson JA; Van Der Saag PT; Van Der Burg BB
    Endocrinology; 2001 Mar; 142(3):1156-66. PubMed ID: 11181531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
    Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The changing role of ER in endocrine resistance.
    Nardone A; De Angelis C; Trivedi MV; Osborne CK; Schiff R
    Breast; 2015 Nov; 24 Suppl 2(0 2):S60-6. PubMed ID: 26271713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
    Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RC-RNase-induced cell death in estrogen receptor positive breast tumors through down-regulation of Bcl-2 and estrogen receptor.
    Tseng HH; Yu YL; Chen YL; Chen JH; Chou CL; Kuo TY; Wang JJ; Lee MC; Huang TH; Chen MH; Yiang GT
    Oncol Rep; 2011 Mar; 25(3):849-53. PubMed ID: 21174060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.
    Frasor J; Weaver A; Pradhan M; Dai Y; Miller LD; Lin CY; Stanculescu A
    Cancer Res; 2009 Dec; 69(23):8918-25. PubMed ID: 19920189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
    Johnston SR; Lu B; Dowsett M; Liang X; Kaufmann M; Scott GK; Osborne CK; Benz CC
    Cancer Res; 1997 Sep; 57(17):3723-7. PubMed ID: 9288779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
    Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
    Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine resistance in breast cancer.
    Zheng LH; Zhao YH; Feng HL; Liu YJ
    Climacteric; 2014 Oct; 17(5):522-8. PubMed ID: 24245601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen.
    Altundag K; Altundag O; Gunduz M; Arun B
    Med Hypotheses; 2004; 63(5):823-6. PubMed ID: 15488654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter.
    Pradhan M; Baumgarten SC; Bembinster LA; Frasor J
    Mol Cell Biol; 2012 Jan; 32(2):569-75. PubMed ID: 22083956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.